natgillin/translations-raw huggingface dataset:
The preference is for A to be located at the C-terminus and the amino is preferably lysine or alternatively another amino acid with a free amino, e.g. 
Derivati peptida GLP-1 u skladu s patentnim zahtjevom 1, naznačeni time što vezna skupina A je amino kiselina sa slobodnim aminom poput ornitina, ili organska skupina sa slobodnim aminom.
Substituted sulphonamides having the general formula (I) wherein 
Supstituirani sulfonamidi sa općom formulom (I) [image] pri čemu
The process of claim 4, wherein the process achieves an overall resid conversion of at least 95 wt. %. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da je ukupna konverzija ostatka najmanje 95 % težinskog udjela.
A method of treating an autoimmune disease comprising administering to a patient in need thereof an isolated antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising: a heavy chain variable region comprising: a first CDR comprising SEQ ID NO:3; 
Izolirano protutijelo koje specifično veže ljudski CD38 (SEQ ID NO: 1) 1 makaki CD38 (SEQ ID NO:2) koje sadrži: a) = varijabilnu regiju teškog lanca koja sadrži SEQ ID NO:9; 1 b) varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10.
the input commands are invoked automatically by the journey of a train, remote activities of other safeguarding equipment or manually by the operator, where 
- se ulazne naredbe pozivaju automatski putovanjem vlaka, udaljenim aktivnostima druge zaštitne opreme ili ručno od strane operatera, gdje HR P20161051 T1
The device according to claim 14, wherein said device is a communication device, in particular a or being associated with a network node, a switching device, an IP DSLAM or an Ethernet switch. 
Uređaj prema zahtjevu 13, gdje je taj uređaj komunikacijski uređaj, posebno je to uređaj ili je povezan s mrežnim čvorom, sklopkom, IP DSLAM ili Ethernet sklopka.
wherein the bioalcohol is bioethanol and/or biobutanol. 
izbornog dobivanja bioalkohola, gdje je bioalkohol bioetanol i/ili biobutanol.
This process needs technically complicated devices and is correspondingly expensive. 
Ovaj proces zahtijeva tehnički složene uređaje 1 u skladu s tim je skup.
Therefore, a further aspect of the present invention relates to the use of the aforementioned pharmaceutical composition for treating a pathological state selected from the group comprising disorders of the central nervous system such as sleep disorders, schizophrenia, and anxiety, disorders of the smooth muscles either of the gastrointestinal system, such as irritable bowel syndrome (IBS), chronic constipation, diarrhoea, and functional dyspepsia or of the cardiovascular system, such as hypertension, myocardial ischemia, cerebral ischemia, migraine, thrombosis, and platelet aggregation, and ocular pathologies such as glaucoma. Examples of suitable dosage forms are tablets, capsules, coated tablets, granules, solutions and syrups for oral administration; solutions, pomade and ointment for topical administration; medicated patches for transdermal administration; suppositories for rectal administration and injectable sterile solutions. 
Uporaba tricikličkog spoja indazola formule (I): u kojoj Y, W, Xi, X», X3, Xay Xs, Lo Lo R4 R2, min imaju značenja definirana u bilo kojem od prethodnih zahtjeva 1 do 8, ili njegove soli s farmaceutski prihvatljivom organskom ili anorganskom kiselinom, naznačena time, da je za pripravu lijeka za liječenje patološkog stanja odabranog iz skupine koju čine poremećaji centralnog nervnog sustava, kao što su poremećaji spavanja, shizofrenia, 1 anksioznost, poremećaji glatkih mišića gastrointestinalnog sustava, kao što su sindrom nadraženih crijeva (IBS), kronična konstipacija, proljev, i funkcionalna dispepsija, 1 poremećaji glatkih mišića kardiovaskularnog sustava, kao što je hipertenzija, miokardijska ishemija, cerebralna ishemija, migrena, tromboza, i agregacija pločastih stanica, te očne patologije, kao što je glaukom.
The invention accordingly provides lozenges, and methods of manufacture thereof, for controlled buccal release and delivery of drugs. 
Izum prema tome prikazuje tablete 1 postupke za njihovu proizvodnju, za kontrolirano oslobađanje u ustima i primjenu lijekova.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least three CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1P, and CCL5/RANTES and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri CC kemokina odabrana iz skupine koja se sastoji od CCL3/MIP-1a, CCLA/MIP-IP, i CCLS/RANTES, a koji se ne veže to CCL2/MCP-I.
Said diodes 104 and 103 are in antiparallel. 
Spomenuta dioda 104 i 103 su u antiparalelnom spoju.
is cyclohexyl, phenyl or pyridyl, which is unsubstituted or mono- or disubstituted by Hal or LA, in Subformula 9 is Hal, LA, O(LA), CN, CONH2, or a monocyclic aliphatic or aromatic homo- or heterocycle having 0,1 or 2 N or O atoms and 5 or 6 skeleton atoms, 
je cikloheksil, fenil ili piridil, koji je nesupstituiran ili mono- ili disupstituiran s Hal ili LA, u Podformuli 9 je Hal, LA, O(LA), CN, CONH2, ili monociklički alifatski ili aromatski homo- ili heterocikal koji ima 0,1 ili 2 N ili O atoma i 5 ili 6 skeletnih atoma,
The method according to one or more of the preceding claims, characterized in that said synthetic substance (4), after the chemical reaction for expansion and setting, in the confinement conditions occurring during use, has a tensile strength substantially ranging from 0.3 MPa to 1.9 MPa for densities ranging substantially from 50 kg/m3 to 200 kg/m3. 
Postupak prema jednom ili više prethodnih zahtjeva, naznačen time, da spomenuta sintetička tvar (4), nakon kemijske reakcije proširenja i postavljanja, u ograničenim uvjetima koji se javljaju prilikom uporabe, ima čvrstoću izvlačenja u rasponu uglavnom od 0,3 MPa do 1,9 MPa za gustoće u rasponu uglavnom od 50 kg/m*do 200 kg/m.
Capsule according to any of the preceding claims, wherein the multi-layer filter comprises at least one layer with openings, wherein the openings are distributed over substantially the entire surface of the filter layer. 
Kapsula prema zahtjevu 11, naznačena time, da tableta obuhvaća najmanje jednu šupljinu koja se proteže od strane tablete koja je okrenuta prema drugoj stijenci, u smjeru treće stijenke kapsule.
In other embodiments, the poly(lactic) acid-poly(ethylene)glycol copolymer has a number average molecular weight of about 16 kDa poly(lactic acid) and a number average molecular weight of about 5 kDa poly(ethylene)glycol. 
Terapeutska nanočestica prema zahtjevu 1, naznačena time da kopolimer poli(mliječna) kiselina-poli(etilen)glikol ima iznos prosječne molekularne težine od 15kDa do 20kDa poli(mliječna) kiselina i iznos prosječne molekularne težine od 4kDa do 6kDa poli(etilen)glikol.
A pharmaceutical composition comprising an effective amount of a crystalline form t of rifaximin according to claim 1 together with pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži djelotvornu količinu kristalnog oblika T rifaksimina u skladu s patentnim zahtjevom 1, uz farmaceutski prihvatljive pomoćne tvari.
Use according to claim 11, wherein the said composition is to be administered orally for the treatment of gastrointestinal irritation disorders and to synergistically improve the antiulcer activity of sucralfate. 
Uporaba prema zahtjevu 11, gdje je ta smjesa namijenjena oralnoj primjeni za liječenje iritabilnih probavnih poremećaja 1 za sinergijsko poboljšanje učinka sukralfata protiv čira.
The preform according to claim 2, wherein the energy absorbing additive is a member being selected from the group consisting of carbon black, graphite, diamond dust, diazonium salts, sulphonium salts, solfoxonium salts, and iodonium salts. 
Postupak prema patentnom zahtjevu 13 naznačen time da je aditiv koji upija energiju član koji je izabran iz skupine koja se sastoji od čađe, grafita, dijamantnog praha, diazonijum soli, sulfonijum soli, sulfoksonijum soli i jodonijum soli.
A composition comprising ivermectin for use to control Dirofilaria immitis and/or Dirofilaria repens infestation in a dog, wherein said ivermectin composition is in the form of an implant, wherein said implant is administered at least once a year and delivers ivermectin under conditions allowing to maintain a concentration of 0.1 ng per mL of plasma during at least 6 months. 
Sastav koji sadrži ivermektin za uporabu u kontroli zaraze Dirofilaria immitis-om i/ili Dirofilaria repens-om u psu, pri čemu je navedeni pripravak ivermektina u obliku implanta, pri čemu se navedeni implant primjenjuje barem jednom godišnje i isporučuje ivermektin pod uvjetima koji omogućuju održavanje koncentracije od 0,1 ng po mL plazme tijekom barem 6 mjeseci.
represents a hydrogen atom or an optionally substituted C1-6 alkyl group; 
R* predstavlja atom vodika ili po izboru supstituiranu C, 4 alkilnu skupinu;
A method according to any of numbered embodiments 1 to 3, wherein the axes of the first and second rotors are arranged such that a line drawn from the axis of the first rotor to the axis of the second rotor makes an angle of from 0 to 20°, below the horizontal. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu su osi prvog 1 drugog rotora raspoređene tako da linija koja se vuče od osi prvog rotora do osi drugog rotora pravi kut od 0 do 20", ispod vodoravne.
Phosphatidylcholine for use in the method of claim 7, wherein said phosphatidylcholine is administered near meal time, or wherein said phosphatidylcholine is administered from about 1 to about 8 times per day, or wherein said phosphatidylcholine is administered about 4 times per day, or wherein the phosphatidylcholine is administered for at least 1 week, or wherein the phosphatidylcholine is administered for at least 2 weeks, or wherein the phosphatidylcholine is administered throughout the life of the individual. 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 7, naznačen time, da se spomenuti fosfatdilkolin primjenjuje neposredno uz vrijeme jela, ili time, da se fosfatdilkolin primjenjuje od oko 1 do oko 8 puta dnevno, ili time, da se fosfatdilkolin primjenjuje oko 4 puta dnevno, ili time, da se fosfatdilkolin primjenjuje najmanje 1 tjedan, ili time, da se fosfatdilkolin primjenjuje najmanje 2 tjedna, ili time, da se fosfatdilkolin primjenjuje kroz cijeli život pojedinca.
the CAR is encoded by the nucleic acid sequence set forth in SEQ ID NO:8. 
(vi) CAR je kodirana sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8
The pharmaceutical or veterinary composition of claim 7 for use in the treatment or the prevention of bacterial infections or disorders associated with bacterial infections in an animal. 
Farmaceutski ili veterinarski pripravak u skladu s patentnim zahtjevom 7, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bakterijskih infekcija ili poremećaja povezanih s bakterijskim infekcijama kod životinje.
A further embodiment of the inventive methods is, therefore, a data carrier (or a digital storage medium, or a computer-readable medium) comprising, recorded thereon, the computer program for performing one of the methods described herein. 
Digitalni medij za pohranu podataka, koji se može čitati preko računala, naznačen time, da obuhvaća pohranjen računalni program koji, dok je programski uključen na računalo, sadrži programski kod za izvršavanje postupka prema zahtjevima 14 ili 15.
compressing the blend from step (3) into tablets; and 
komprimiranja smjese iz koraka (4) u tablete; i
The method of claim 3, wherein the CH3-domain of the 1st antibody heavy chain further comprises a substitution of the amino acid residue at position 351 according to the EU numbering system by a lysine (K) residue. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni prvi polipeptidni lanac koji sadrži CH3 domenu dalje sadrži ostatak lizina (K) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije.
optionally e′) when R4′ is —CH2CO2-alkyl, (i) a step of reduction, optionally followed by (ii) methyl ether formation; and 
e’) kada je R4’ reducirani prekursor hidroksietila i zato slijedeći prekursor metoksietila, za korakom redukcije opcijski slijedi tvorba metil etra;
The nano-fibrillar cellulose gel according to claim 15, characterized in that the Brookfield viscosity of the nano-fibrillar cellulose gel is lower than the Brookfield viscosity of a corresponding nano-fibrillar cellulose suspension having been fibrillated in the absence of fillers and/or pigments. 
Gel od nanofibrilarne celuloze u skladu s patentnim zahtjevom 15, naznačen time što viskoznost gela od nanofibrilarne celuloze prema Brookfieldu je manja od viskoznosti odgovarajuće suspenzije nanofibrilarne celuloze prema Brookfieldu jer je fibrilirana u odsutnosti punila i/ili pigmenata.
dispersing HPMC in said first vessel; dissolving said prodrug compound in water to form a solution, and adding said solution to said first vessel; adding a second anti-solvent to said solution in said first vessel so as to crystallize said compound on the inside and on the surface of said HPMC and thereby form said formulation, wherein said second anti-solvent is a combination consisting essentially of acetone and isopropyl acetate (IPAC). 
Cc) - otapanje navedenog spoja koji je predlijek u otapalu kako bi se dobila otopina, te dodavanje navedene otopine u navedenu prvu posudu; d) = dodavanje drugog protuotapala u navedenu otopinu u navedenoj prvoj posudi kako bi se kristalizirao navedeni spoj s navedenim HPMC i tako dobila navedena formulacija, gdje je navedeno drugo protuotapalo kombinacija koja se uglavnom sastoji od acetona i izopropil-acetata (IPAC).
In another aspect, the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in association with at least one pharmaceutically acceptable excipient, carrier or diluent. 
Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 4 ili 5, naznačen time da je navedeno korištenje u kombinaciji s najmanje jednim sredstvom za poboljšavanje kognitivnih funkcija, sredstvom za pospješivanje pamćenja 1li inhibitorom kolin esteraze.
treating or preventing a condition associated with c-fins in a patient, said condition optionally being cancer, the cancer optionally being selected from the group consisting of breast cancer, prostate cancer, endometrial adenocarcinoma, leukemia, lymphoma, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, and ovarian cancer, or 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 17, naznačeno time što se rak bira iz skupine koju čine rak dojke, rak prostate, kolorektalni rak, adenokarcinom endometrija, leukemija, limfom, melanom, rak pločastih stanica jednjaka, rak želuca, astrocitni rak, rak endometrija, rak vrata maternice, rak mokraćnog mjehura, rak bubrega, rak pluća i rak jajnika.
dividing said fat into cell agglomerates smaller than said macroagglomerates, so that said cell agglomerates are as large as or smaller than a predetermined size, and so that they are on average of the same size, which size reducing step is carried out by causing said extracted lobular fat to pass at least once through said size reducing means (3), manual or mechanical stirring of the washing and separating container (1) for obtaining an emulsion of the fluid components, such as blood fluids, blood residues, oils and other solutions contained in the liposuctioned material allowing said fluids to remain separate from the solid cell material without the use of enzymes or chemicals; 
- manualnog ili mehaničkog miješanja navedenog spremnika (1) za ispiranje i odvajanje radi dobivanja emulzije fluidnih komponenti, kao što su fluidi krvi, ostaci krvi, ulja i druge otopine koje su sadržane u materijalu koji je dobiven liposukcijom čime se omogućava navedenim tekućinama da ostanu odvojene od čvrstog staničnog materijala bez upotrebe enzima ili kemikalija, -
Fig. 11 shows the detachable wall member 21 for providing fluid channels and/or guiding passages within the tubular member 4, see description of fig. 4 above. 
Slika 11 prikazuje element stijenke 21 koji se može odvojiti 1 koji ima kanale za fluid i/ili prolaze za vođenje unutar cijevnog elementa 4, vidi gore navedeni opis slike 4. HR P20090033 T3
compounds of the formula (XVI a,b) A compound of the formula (XVIII) and the salts, solvates and solvates of the salts thereof. 
XVI a+b 7. > Spoj s formulom (XVIII), i soli, solvati i solvati njihovih soli.
Moreover, the compounds employed in the present invention may stimulate inhibitory pathways in cells, particularly in leukocytes, lung epithelial cells, or both, and are thus useful in treating such diseases. 
Osim toga, spojevi koji se koriste u prikazanom izumu mogu stimulirati inhibiciju kaskada u stanicama, naročito u leukocitima, stanicama plućnog epitela ili u obje situacije i tako su korisni za liječenje takvih bolesti.
The compound for use according to claim 22, wherein the condition is psoriasis or sarcoidosis. 
Spoj za uporabu prema zahtjevu 21, naznačen time da je stanje psorijaza ili sarkoidoza.
It can have all kinds of shapes, such as e.g. a pad or a cup-like shape. 
Može imati sve vrste oblika, takve kao što je, na primjer, jastučić ili može imati oblik koji je sličan čašici.
The advantages of system 10 would therefore include a relatively small-sized, interchangeable, removable bottle 20 that could be handled by hand, in combination with a fluid pump and air compressor to provide an aerated fluid flow to produce a mist of even consistency and application; all without having to use an atomization or atomizer structure or method, which can be expensive and could be detrimental to biological cells or life forms. 
Prednosti sustava 10 obuhvaćaju relativno malu, međusobno zamjenjivu, odvojivu bocu 20 kojom se može ručno manipulirati, u kombinaciji s jednom pumpom za fluid i jednim kompresorom da bi se dobio protok fluida pomiješanog sa zrakom kako bi se proizvela magla ravnomjerne konzistencije i nanošenja, a sve bez korištenja rasitnjavanja ili neke strukture ili postupka za usitnjavanje koja može biti skupa i razarajuća za biološke stanice ili žive oblike.
A method for producing high-printability coated paper, characterized in that it comprises the step of depositing, by coating, on at least one face of a paper substrate, a composition comprising a polyurethane-based polymeric material in a percentage comprised between 65% and 90% by weight of the total weight and latex in a percentage comprised between 5% and 20% by weight of the total weight, the composition comprising talc in a percentage below 20% by weight of the total weight, said polyurethane-based polymeric material comprising a film-forming bonding agent, which comprises dispersions of anionic urethane polymers having aliphatic rigid segments and flexible polyether and polyester segments, said composition being applied on said at least one face in a quantity comprised between 3 g/m2 and 15 g/m2, preferably between 5 g/m2 and 10 g/m2 said talc having an average diameter of 2.0 microns and a particle size distribution such that at least 45% of the particles have a diameter of less than 2 microns.. 
Postupak proizvodnje premazanog papira visoke printabilnosti, naznačen time, da obuhvaća fazu nanošenja premazivanjem najmanje jedne strane papirnate podloge smjese koja sadrži polimerni materijal na bazi poliuretana u rasponu između 65 % 1 90 % masenog udjela u cjelokupnoj masi i lateks u rasponu između 5 % i 20 % masenog udjela u cjelokupnoj masi, smjesa sadrži manje od 20 % masenog udjela talka u cjelokupnoj masi, navedeni polimerni materijal na bazi poliuretana sadrži vezivno sredstvo koje tvori prevlaku, a sadrži disperziju anionskih polimera uretana s alifatnim krutim segmentima i fleksibilnim polieternim i poliesternim segmentima, navedena smjesa nanosi se najmanje na jednu navedenu stranice u količini od 3 g/m* do 15 g/m'", poželjno je između 5 g/m? do 10 g/m', prosječni promjer čestica navedenog talka iznosi 2,0 mikrona s takvom distribucijom veličine čestica da najmanje 45 % čestica ima promjer manji od 2 mikrona.
The method according to one or more of claims 28 or 29, characterized in that all the needles of the needle cylinder of the machine are made to knit at said second drop and at said fourth drop and only part of the needles of the needle cylinder of the machine, uniformly distributed along the circumferential extension of the needle cylinder according to a preset needle selection, are moved to knit at said first drop and said third drop, while the needles that are not made to knit, at said first drop and at said third drop, pass with their beak below the sinkers, retaining in their beak the last loop of knitting formed at the previous drop in order to knit it in with a new loop at the next drop. 
Postupak prema jednom ili više prethodnih zahtjeva 15 do 29, naznačen time, da se sve igle u cilindru s iglama na stroju postave za pletenje na spomenutom drugom transporteru i na spomenutom četvrtom transportu, a da se samo dio igala iz cilindra s iglama na stroju, koje su jednoliko raspoređene uzduž obodnog produženja cilindra s iglama u skladu s prethodno utvrđenim izborom igala, kreće zbog pletenja na spomenutom prvom i spomenutom trećem transporteru, dok igle, koje se na spomenutom prvom i spomenutom trećem transporteru ne koriste za pletenje, prolaze mimo tih transportera, dok se njihovi kljunasti vrhovi nalaze ispod ispusta, pri čemu njihovi kljunasti vrhovi dalje drže posljednju ispletenu očicu, izrađenu na prethodnom transporteru, da bi se ispletenu očicu uplelo s novom očicom na slijedećem transporteru.
Floor panel according to any of the preceding claims, characterized in that the core of the floor panel (1) consists of wood, a product on the basis of wood or synthetic material. 
Podni panel prema patentnom zahtjevu 9 ili 10, naznačen time što se zasebni umetak sastoji od okretnog elementa za blokiranje.
Composition for the use according to claim 1, wherein X2 is an amino acid residue selected from the group consisting of lysine (K) and arginine (R) and/or X6 is alanine (A). 
Sastav za uporabu prema zahtjevu 1, naznačen time, da X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K) i arginin (R) i/ili X; je alanin (A).
An object of the present invention is also a method for producing at least one fermentation product, comprising a step of fermentation, under anaerobic conditions, by a yeast as defined above in a fermentation medium. 
Postupak proizvodnje najmanje jednog fermentacijskog produkta, naznačen time što se sastoji u koraku fermentacije u anaerobnim uvjetima sojem kvasca u skladu s patentnim zahtjevom 7 u fermentacijskom mediju.
providing a solvent composition comprising methyl soyate, N- methylpyrrolidinone, an additional solvent, and a cationic surfactant; contacting the contaminant material with the solvent composition; and 
(A) osiguravanja da se formulacija otapala sastoji od metil-sojata, N-metilpirolidinona, dodatnog otapala, sredstva za raspršivanje i kationskog surfaktanta;
The process of claim 1, wherein less than 1% of the API dissolves in a dissolution test indicative of taste-release in the mouth in 120 seconds. 
Postupak sukladno zahtjevu 1, naznačeno time, da se manje od 1%, ili manje od 0.5 % API-ja otapa u testu otapanja indikatora otpuštanja okusa za 120 sekundi.
A similar embodiment is shown in FIG. 4, wherein the channel 20 is arranged transversally with respect to the plane passing through the groove 16 . 
Karabiner (1) u skladu s patentnim zahtjevom 4, naznačen time što je kanal (20) smješten poprečno u odnosu na ravninu koja prolazi kroz žlijeb (16).
EP0376518; European Patent Application No. 
(96) Broj europske prijave patenta:
The composition according to any of claims 1-7, wherein said compound is 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine HBr in an amount of 1-50 mg. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 1-7, pri čemu je navedena tvar 1-[2-(2,4-dimetil-fenilsulfan1l)- fenillpiperazin HBr u količini od 1-50 mg.